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AN ASSESSMENT OF THE UPDATED RESULTS
FROM THE ARIMIDEX,TAMOXIFEN, ALONE 
OR IN COMBINATION (ATAC) TRIAL: AN
EVIDENCE-BASED MEDICINE APPROACH
Edwards SJ
AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom
OBJECTIVE: To assess the main outcomes from the
updated results of the Arimidex, Tamoxifen, Alone, or 
in Combination (ATAC) trial as beneﬁts or harms using
numbers needed to treat (NNT) and numbers needed to
harm (NNH). METHODS: The ATAC trial is a ran-
domised, double blind, clinical trial being conducted 
in 381 centres in 21 countries involving 9366 patients.
ATAC compares anastrozole 1mg, alone or in combina-
tion with tamoxifen 20mg, relative to tamoxifen 20mg
alone as 5-year adjuvant treatment for postmenopausal
women with early breast cancer. The primary analysis
was performed when the required number of events 
had occurred, at a median of 33.3 months. A subsequent
intention-to-treat analysis has been conducted at 47-
months and this data was used as the basis for the cal-
culation of NNTs and NNHs. RESULTS: In terms of
beneﬁts, the NNT for anastrozole compared to tamox-
ifen to have one additional patient disease-free at 4 years
is 35 (hormone-receptor positive subgroup) or 42 (overall
population). Similarly the NNT for anastrozole compared
to tamoxifen to prevent one additional patient experi-
encing a ﬁrst-event at 4 years is 46 (hormone-receptor
positive subgroup) or 52 (overall population). In terms of
harm, the NNH for tamoxifen compared to anastrozole
to cause one additional thromboembolic event at 4 years
is 65. Conversely, the NNH for anastrozole compared to
tamoxifen to cause one additional fracture at 4 years is
38. CONCLUSIONS: The available data from the ATAC
trial demonstrates signiﬁcant beneﬁts for patients treated
with anastrozole rather than tamoxifen. Anastrozole and
tamoxifen have different side-effect proﬁles and these
should be taken into consideration when assessing the
risk proﬁle of individual patients.
PCN2
BREAST CANCER PATIENTS’ USE OF HEALTH
CARE INFORMATION IN DECISION-MAKING
AND IN COPING WITH ILLNESS: RESULTS OF A
QUALITATIVE STUDY
Swaney J, Longo DR, Radina ME
University of Missouri-Columbia, Columbia, MO, USA
OBJECTIVE: Due to advances in treatment, breast cancer
patients, who constitute the largest group of cancer sur-
vivors, face complex treatment options and are among the
most active health care consumers. This study determines
how breast cancer patients access and use health care
information to make treatment decisions. METHODS: A
qualitative study using in-depth interviews with a cross-
section of patients recruited from oncology clinics and a
breast cancer support group. Interviews were audio taped
and transcribed. RESULTS: Theoretical saturation was
achieved following interviews with 20 patients. The mean
age was 49.1 years and median time since diagnosis 
was 20 months. Thirteen (65%) patients were educated
beyond high school and all were white. Two patients were
pre-op, 10 were post-op and receiving active therapy, 4
were post-up under surveillance, and 4 in relapse. Seven-
teen patients (85%) sought information outside of that
provided by the treatment team, 2 (10%) did not seek
outside information but used that provided by friends or
family, and 1 (5%) did not seek or use outside infor-
mation. The Internet was the most frequently cited 
information source (N = 14, 70%) followed by books,
magazines, friends and family, television, and newspa-
pers. Patients actively sought information while in all
phases of care, including survivorship, but the type of
information they sought varied across phases. Most relied
heavily on their physician’s advice in making treatment
decisions and sought outside information as a means of
coping with illness rather than in decision-making. CON-
CLUSIONS: Breast cancer patients frequently seek
outside information, often from the Internet, and use this
information primarily to cope with illness rather than to
make treatment decisions. Therefore, in order to ensure
patient-centered care, it is important to learn more about
the information needs of women at various stages of
treatment and survivorship to provide appropriate and
meaning health information for this population.
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OBJECTIVES: To depict current clinical practice in the
treatment of local, locally advanced and metastatic
(stages I/II, III, and IV respectively) Breast Cancer in
Greece. METHODS: A group of 7 Breast Cancer experts
gave information about current therapeutic approaches
and their frequency of usage in the treatment of breast
cancer patients. Data were derived from retrospective
